Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
$10.80
-2.1%
$6.68
$4.92
$25.58
$5.50M1.34136,759 shs91,305 shs
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
$13.14
+3.1%
$14.27
$7.05
$17.15
$345.71M0.3755,949 shs74,946 shs
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
$0.05
$0.06
$0.13
$0.38
$4.12M1.33338,444 shs15,461 shs
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
$2.00
+1.0%
$0.83
$0.94
$7.76
$5.95M0.721.63 million shs29,428 shs
Q Biomed Inc. stock logo
QBIO
Q Biomed
$0.00
$0.00
$0.03
N/A2.198,584 shsN/A
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.00%+56.22%+62.82%+96.07%+32.29%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
0.00%+15.77%-13.38%+6.66%+48.64%
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
-3.03%-2.77%-26.29%-22.54%+49.84%
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
0.00%+8.11%+1,011.11%+957.64%+4.19%
Q Biomed Inc. stock logo
QBIO
Q Biomed
0.00%0.00%0.00%-50.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
2.9798 of 5 stars
3.65.00.00.02.40.00.6
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
2.0176 of 5 stars
3.62.00.00.02.50.80.0
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
N/AN/AN/AN/AN/AN/AN/AN/A
Q Biomed Inc. stock logo
QBIO
Q Biomed
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
3.20
Buy$33.00205.70% Upside
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
3.22
Buy$23.8381.38% Upside
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
0.00
N/AN/AN/A
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
0.00
N/AN/AN/A
Q Biomed Inc. stock logo
QBIO
Q Biomed
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NTN, BNTC, MATN, QBIO, and ARTL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/6/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
5/19/2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
5/15/2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.00
4/28/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
4/10/2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$18.00 ➝ $20.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/A$5.31 per shareN/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/A$4.68 per shareN/A
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
N/AN/AN/AN/A$0.20 per shareN/A
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
$19.81M0.30$0.46 per share4.38$1.76 per share1.14
Q Biomed Inc. stock logo
QBIO
Q Biomed
$280KN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$9.83M-$17.94N/AN/AN/AN/A-226.99%-164.61%8/12/2025 (Estimated)
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$21.75M-$1.51N/AN/AN/AN/A-38.26%-35.71%N/A
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
-$6.64MN/A0.00N/AN/AN/A-64.66%-42.92%N/A
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
-$2.05MN/AN/AN/A-61.42%-162.54%-49.94%N/A
Q Biomed Inc. stock logo
QBIO
Q Biomed
-$2.05MN/A0.00N/AN/AN/AN/AN/AN/A

Latest NTN, BNTC, MATN, QBIO, and ARTL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q3 2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$0.36-$0.24+$0.12-$0.24N/AN/A
5/13/2025Q1 2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$0.78-$4.32-$3.54-$0.72N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/AN/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/AN/A
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
N/AN/AN/AN/AN/A
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
N/AN/AN/AN/AN/A
Q Biomed Inc. stock logo
QBIO
Q Biomed
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/A
0.49
0.49
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
0.01
14.80
14.80
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
N/A
0.17
0.17
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
3.30
0.95
0.95
Q Biomed Inc. stock logo
QBIO
Q Biomed
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.87%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
52.19%
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
0.07%
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
6.31%
Q Biomed Inc. stock logo
QBIO
Q Biomed
N/A

Insider Ownership

CompanyInsider Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.83%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
1.30%
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
39.22%
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
24.20%
Q Biomed Inc. stock logo
QBIO
Q Biomed
28.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
5550,000542,000Not Optionable
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
2026.25 million25.91 millionNo Data
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
1390.24 millionN/ANot Optionable
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
192.98 millionN/ANot Optionable
Q Biomed Inc. stock logo
QBIO
Q Biomed
3N/AN/ANot Optionable

Recent News About These Companies

Q BioMed Inc
Orchestra Biomed Reports Q3 2024 Financial Results
A Powerful New Tool for Biomedical Research
Q BioMed Inc QBIO
Biomedical Sciences PhD Program
QBIO Q BioMed Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artelo Biosciences stock logo

Artelo Biosciences NASDAQ:ARTL

$10.80 -0.24 (-2.13%)
Closing price 07/3/2025 03:49 PM Eastern
Extended Trading
$10.80 0.00 (0.00%)
As of 07/3/2025 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Benitec Biopharma stock logo

Benitec Biopharma NASDAQ:BNTC

$13.14 +0.40 (+3.14%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Mateon Therapeutics stock logo

Mateon Therapeutics OTCMKTS:MATN

$0.05 0.00 (0.00%)
As of 07/3/2025

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.

NTN Buzztime stock logo

NTN Buzztime NYSEAMERICAN:NTN

$2.00 +0.02 (+1.01%)
As of 07/3/2025

NTN Buzztime, Inc., together with its subsidiaries, provides interactive entertainment and technology to bars, restaurants, casinos, and senior living centers in the United States and Canada. Its principal product and service is its tablet platform. The company also leases equipment, including tablets, and cases and charging trays for the tablets to various network subscribers. It also licenses its content to customers to be installed on equipment that they obtain from other parties. The company's interactive entertainment system offers trivia, card, sports, and arcade games. It owns various trademarks, including the Buzztime, Playmaker, Mobile Playmaker, and BEOND Powered. As of June 30, 2020, NTN Buzztime, Inc. served 1,219 venues with its interactive entertainment network. The company was formerly known as NTN Communications, Inc. and changed its name to NTN Buzztime, Inc. in 2005. NTN Buzztime, Inc. was founded in 1982 and is based in Carlsbad, California.

Q Biomed stock logo

Q Biomed OTCMKTS:QBIO

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.